If You Invested in Volitionrx (VNRX)

VolitionRx Limited (NYSE American: VNRX) is a multi-national epigenetics company operating in the surgical and medical instrument manufacturing industry. Through its subsidiaries, the company focuses on advancing the science of epigenetics by developing and commercializing simple, easy-to-use, cost-effective blood tests designed to help detect and monitor a range of life‑altering diseases. According to company disclosures, these include some cancers and diseases associated with NETosis, such as sepsis.

VolitionRx describes itself as dedicated to saving lives and improving outcomes for people and animals through earlier detection and through disease and treatment monitoring. Its approach is based on the science of Nucleosomics, the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluids as an indication that disease may be present. The company applies this platform to human diagnostics and monitoring and also operates a subsidiary focused on animal diagnostics and monitoring.

Core technology and product pillars

VolitionRx’s work centers on epigenetic biomarkers and nucleosome-based assays. The company highlights several branded technology pillars and assay families:

• Nu.Q® platform – a family of blood tests that measure nucleosome biomarkers. Volition states that Nu.Q® assays are being developed and commercialized to support detection and monitoring of diseases, including cancers and NETosis‑associated conditions such as sepsis.
• Nu.Q® Cancer assays – assays used in the management of lung cancer patients, including as prognostic biomarkers. Company communications describe studies where methylated nucleosome biomarkers (such as H3K27Me3‑nucleosomes) are evaluated for their association with disease stage, survival, and risk stratification in non‑small cell lung cancer.
• Nu.Q® NETs assays – assays focused on NETosis and neutrophil extracellular traps (NETs). Volition reports that Nu.Q® NETs H3.1 is being evaluated as a marker that can distinguish sepsis from non‑infectious systemic inflammation, correlate with disease severity, and provide prognostic information for outcomes such as organ failure and mortality.
• Nu.Q® Vet Cancer Test – a veterinary screening blood test intended for use during regular preventive check‑ups of older dogs or younger dogs of high‑risk breeds. Volition indicates that this test is available in more than 20 countries and is used as a non‑invasive, cost‑effective tool to support earlier cancer detection in canines.
• Nu.Q® Vet Feline assay – a feline assay under development. Volition has announced clinical data for a Nu.Q® Vet Feline test aimed at detecting lymphoma in cats, describing high specificity and substantial detection rates in a study cohort.
• Nu.Q® Discover – a pillar through which Volition supplies biomarkers to pharmaceutical and diagnostic company clients in human clinical studies, including use in a longitudinal Phase 1/2b study to support drug development and disease research.
• Capture‑Seq™ – a method described by Volition for physical enrichment and analysis of ultrashort transcription factor‑bound DNA fragments in plasma as liquid biopsy biomarkers. The company reports that this approach can enrich ultrashort DNA fragments and reduce background DNA, with the goal of enabling accurate, lower‑cost cancer testing based on epigenetically altered chromatin fragments.
• High Throughput NETs method – a proprietary method that measures NETs activation and inhibition in whole blood in real time, used by companies developing therapeutics for sepsis and other NETs‑related diseases.

Human health focus: cancer and sepsis

In human diagnostics, VolitionRx emphasizes applications in oncology and critical care. The company reports:

• Nu.Q® Cancer assays being used in large‑scale studies of lung cancer, where circulating nucleosome biomarkers (including H3K27Me3‑nucleosomes) are evaluated for prognostic value, recurrence‑free survival, and support for treatment decision‑making.
• Inclusion of its Nu.Q® NETs H3.1 assay as the sole biomarker in a French government‑backed real‑world program (DETECSEPS) evaluating early detection of sepsis, alongside a clinical score (NEWS2) on an automated analyzer platform.
• Use of Nu.Q® NETs assays across multiple hospitals and clinical indications related to NETosis, with the company positioning NETs testing as a potential component of routine blood testing in the future.
• Development of a bedside lateral flow test for point‑of‑care quantification of nucleosomes, described as providing a quantitative readout to support clinical decision‑making in settings such as sepsis and other NETosis‑related conditions.

VolitionRx also reports that it is pursuing licensing and co‑marketing arrangements with diagnostic and liquid biopsy companies, and has signed agreements relating to specific indications such as antiphospholipid syndrome. The company indicates that it is in discussions with multiple diagnostic and liquid biopsy companies at various stages, from due diligence to term sheet negotiation, with the goal of licensing its platform for broad clinical deployment.

Veterinary diagnostics and animal health

Beyond human health, VolitionRx operates a veterinary diagnostics business through Volition Veterinary Diagnostics Development, LLC. The company states that:

• The Nu.Q® Vet Cancer Test is used as a screening tool in dogs, particularly older animals and those from high‑risk breeds, and is available in more than 20 countries.
• The Nu.Q® Vet Canine test is described as a leading canine cancer screening blood test by volume, with substantial sales reported in a recent year.
• Nu.Q® Vet Feline assay development has produced clinical data for lymphoma detection in cats, with the company highlighting the potential to provide a simple, affordable blood‑based liquid biopsy test for feline cancer.
• Volition has engaged in corporate social responsibility initiatives, such as donating Nu.Q® Vet Cancer Tests to support crisis response dogs working in disaster and trauma settings.

Research footprint and geographic presence

VolitionRx reports that its research and development activities are centered in Belgium. It also notes that it maintains an innovation laboratory and office in the United States and an office in London. The company is incorporated in Delaware and lists its principal executive offices in Henderson, Nevada in SEC filings.

Capital markets activity and corporate structure

VolitionRx Limited is listed on the NYSE American under the ticker symbol VNRX. SEC filings show that the company has undertaken various capital‑raising transactions, including underwritten public offerings of common stock and warrants, registered direct offerings, and a senior secured convertible promissory note and warrant financing with an institutional investor. The company has also increased its authorized share capital through amendments to its certificate of incorporation.

The company’s obligations under certain financing arrangements, such as a senior secured convertible promissory note, are secured by a first‑priority security interest in its assets and guaranteed by its subsidiaries, according to its Form 8‑K disclosures. These filings describe terms such as conversion prices, repayment schedules, ownership limitations, and conditions for events of default.

Business model characteristics

Based on its disclosures, VolitionRx pursues a model that combines:

• Development and commercialization of proprietary blood‑based diagnostic assays in human and veterinary markets.
• Licensing and co‑marketing agreements with large diagnostic and liquid biopsy companies and other partners, which may include up‑front payments, milestone payments, and potential recurring revenue.
• Collaboration with academic medical centers, hospitals, and pharmaceutical companies for clinical studies, validation of biomarkers, and use of Nu.Q® Discover biomarkers in drug development.

Regulatory and reporting profile

As a U.S. public company, VolitionRx Limited files periodic and current reports with the U.S. Securities and Exchange Commission, including Forms 10‑Q, 10‑K, and 8‑K. These filings cover financial results, capital raising transactions, changes to its charter, and material agreements. The company also files registration statements for offerings of common stock and warrants. Investors can review these documents to understand VolitionRx’s financial condition, risk factors, and detailed contractual terms.

Evergreen considerations

The description above focuses on structural aspects of VolitionRx’s business that are less likely to change quickly: its focus on epigenetics and Nucleosomics, its Nu.Q® and Capture‑Seq™ technology pillars, its dual emphasis on human and veterinary diagnostics, and its role as a developer and licensor of nucleosome‑based blood tests. For the latest financial data, clinical milestones, and partnership details, investors should consult the company’s most recent SEC filings and press releases.